Latest news with #RNAi
Yahoo
3 days ago
- Business
- Yahoo
Alnylam Pharmaceuticals, Inc. (ALNY) Gets EU Nod for AMVUTTRA
We recently compiled a list of Alnylam Pharmaceuticals, Inc. stands eighth on our list and recently got approval for AMVUTTRA. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is a leading biopharmaceutical company specializing in RNA interference (RNAi) therapeutics, with four FDA-approved drugs for rare genetic diseases. Recently, the company has made significant strides in treating transthyretin amyloidosis (ATTR), a progressive disease affecting the heart and nerves. In March 2025, the FDA approved AMVUTTRA (vutrisiran) to reduce cardiovascular death and hospitalizations in ATTR-CM patients, based on strong results from the HELIOS-B Phase 3 trial. The drug also received approval from the European Commission in June 2025. Long-term data (up to 42 months) continues to support its effectiveness in improving heart function and quality of life. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), considered one of the most undervalued stocks in the biotech sector, is advancing nucresiran (ALN-TTRsc04), a next-gen RNAi treatment for ATTR. Interim Phase 1 results show sustained TTR protein reduction (over 90% within 15 days), with potential for once- or twice-yearly dosing. The drug enters Phase 3 trials in 2025 through the TRITON-CM program, aiming for longer-lasting, more convenient treatment options. A close-up of a staff member counting pills in a pharmaceutical warehouse. Beyond ATTR, the business is expanding its pipeline with nine new investigational therapies by the end of 2025, including treatments for Huntington's disease, bleeding disorders, and type 2 diabetes. The company also initiated a landmark Phase 1 trial for ALN-HTT02 in Huntington's, marking its entry into neurotherapeutics. Platform upgrades are targeting improved delivery to organs like the brain, heart, and kidneys, enhancing Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)'s ability to address both rare and common diseases. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
22-07-2025
- Business
- Yahoo
Biogen to invest further $2bn in North Carolina's Research Triangle Park
Biogen has announced plans to invest an additional $2bn in Research Triangle Park (RTP) in the US state of North Carolina. The latest manufacturing investment will support the ongoing development of Biogen's late-stage clinical pipeline. Since its establishment in 1995, the company's manufacturing in RTP has been crucial in providing innovative treatments to millions of patients globally. The company has invested $10bn in its North Carolina manufacturing, and plans to enhance its investments in various modalities and facilities at its two campuses in RTP. These funds will involve expanding its antisense oligonucleotide (ASO) capabilities and infrastructure, developing multi-platform fill-finish capabilities for clinical and commercial use, and further modernising manufacturing technologies and controls through AI and advanced automation. Biogen pharmaceutical operations and technology head Nicole Murphy stated: 'We are proud of our longstanding commitment to manufacturing innovation, investment and collaboration with the Research Triangle Park community. 'Our manufacturing footprint in the US has played a critical role in Biogen's history and success, and in advancing the treatments that are making an impact for patients, families and communities here in the US and around the world. 'With this investment, we will modernise and expand our manufacturing capability to enable our pipeline and provide resilient patient supply, while continuing to support the skilled and dedicated community of life sciences talent in North Carolina.' More than 90% of the advanced commercial medicines developed by Biogen undergo manufacturing and quality control testing in the US. In May 2025, Biogen and City Therapeutics collaborated to develop RNA interference (RNAi) therapy. Biogen agreed to pay City Therapeutics $46m: $16m upfront and $30m investment in the form of a convertible note. "Biogen to invest further $2bn in North Carolina's Research Triangle Park" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
21-07-2025
- Business
- Yahoo
Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Third Quarter Results
PASADENA, Calif., July 21, 2025--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on August 7, 2025, at 4:30 p.m. ET to discuss its financial results for the fiscal 2025 third quarter ended June 30, 2025. Webcast and Conference Call and Details Investors may access a live audio webcast on the Events and Presentations page under the Investors section of the Arrowhead website. A replay of the webcast will be available approximately two hours after the conclusion of the call. For analysts that wish to participate in the conference call, please register at Once registered, you will receive the dial-in number and a personalized PIN code that will be required to access the call. About Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead's RNAi-based therapeutics leverage this natural pathway of gene silencing. For more information, please visit or follow us on X (formerly Twitter) at @ArrowheadPharma, LinkedIn, Facebook, and Instagram. To be added to the Company's email list and receive news directly, please visit Safe Harbor Statement under the Private Securities Litigation Reform Act: This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this release except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "expect," "believe," "anticipate," "hope," "intend," "plan," "project," "could," "estimate," "continue," "target," "forecast" or "continue" or the negative of these words or other variations thereof or comparable terminology are intended to identify such forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our business, expectations for our product pipeline or product candidates, including anticipated regulatory submissions and clinical program results, prospects or benefits of our collaborations with other companies, or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements include, but are not limited to, statements about the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs; our expectations regarding the potential benefits of the partnership, licensing and/or collaboration arrangements and other strategic arrangements and transactions we have entered into or may enter into in the future; our beliefs and expectations regarding milestone, royalty or other payments that could be due to or from third parties under existing agreements; and our estimates regarding future revenues, research and development expenses, capital requirements and payments to third parties. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of numerous factors and uncertainties, including the impact of the ongoing COVID-19 pandemic on our business, the safety and efficacy of our product candidates, decisions of regulatory authorities and the timing thereof, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, the enforcement of our intellectual property rights, and the other risks and uncertainties described in our most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other documents filed with the Securities and Exchange Commission from time to time. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances. Source: Arrowhead Pharmaceuticals, Inc. View source version on Contacts Arrowhead Pharmaceuticals, Anzalone, CFA626-304-3400ir@ Investors: LifeSci Advisors, LLCBrian Ritchie212-915-2578britchie@ Media: LifeSci Communications, LLCKendy Guarinoni, Ph.D.724-910-9389kguarinoni@
Business Standard
17-07-2025
- Business
- Business Standard
Anthem Biosciences IPO ends with 63.86x subscription
The offer received bids for 281.45 crore shares as against 4.40 crore shares on offer. The initial public offer of Anthem Biosciences received bids for 2,81,45,24,128 shares as against 4,40,70,682 shares on offer. The issue was subscribed 63.86 times. The Qualified Institutional Buyers (QIBs) category was subscribed 182.65 times. The Non-Institutional Investors (NIIs) category was subscribed 42.36 times. The Retail Individual Investors (RIIs) category was subscribed 5.64 times. The issue opened for bidding on 14 July 2025 and it closed on 16 July 2025. The price band of the IPO is fixed between Rs 540 and 570 per share. The IPO is a full offer for sale of 5,95,61,404 equity shares at the upper price, amounting to Rs 3,395 crore. The company will not receive any funds from the offer; all proceeds will go to the selling shareholders based on the shares they offered. The promoters and promoter group hold a total of 43,17,47,949 equity shares, making up 76.87% of the pre-offer issued and paid-up equity share capital. Their shareholding after the IPO is expected to be around 74.69%. Anthem Biosciences is a tech-oriented CRDMO, providing drug discovery and manufacturing services, as well as specialty ingredients like probiotics, enzymes, and peptides. In FY25, CRDMO contributed 81.65% of its revenue. It serves over 550 clients in more than 44 countries, with Europe and North America being key markets. Supported by green chemistry and a partnership with Davos Pharma in the U.S., the company is growing its capacity and working on technologies like RNAi and ADCs. Ahead of the IPO, Anthem Biosciences on Friday, 11 July 2025, raised Rs 1,016.02 crore from anchor investors. The board allotted 1.78 crore shares at Rs 570 each to 60 anchor investors. The firm reported a consolidated net profit of Rs 451.26 crore and sales of Rs 1,844.55 crore for the twelve months ended on 31 March 2025.
Business Standard
15-07-2025
- Business
- Business Standard
Anthem Biosciences IPO subscribed 3.28 times
The offer received bids for 14.47 crore shares as against 4.40 crore shares on offer. The initial public offer of Anthem Biosciences received bids for 14,47,66,596 shares as against 4,40,70,682 shares on offer, according to stock exchange data at 17:00 IST on Tuesday (15 July 2025). The issue was subscribed 3.28 times. The issue opened for bidding on 14 July 2025 and it will close on 16 July 2025. The price band of the IPO is fixed between Rs 540 and 570 per share. An investor can bid for a minimum of 26 equity shares and in multiples thereof. The IPO is a full offer for sale of 5,95,61,404 equity shares at the upper price, amounting to Rs 3,395 crore. The company will not receive any funds from the offer; all proceeds will go to the selling shareholders based on the shares they offered. The promoters and promoter group hold a total of 43,17,47,949 equity shares, making up 76.87% of the pre-offer issued and paid-up equity share capital. Their shareholding after the IPO is expected to be around 74.69%. Anthem Biosciences is a tech-oriented CRDMO, providing drug discovery and manufacturing services, as well as specialty ingredients like probiotics, enzymes, and peptides. In FY25, CRDMO contributed 81.65% of its revenue. It serves over 550 clients in more than 44 countries, with Europe and North America being key markets. Supported by green chemistry and a partnership with Davos Pharma in the U.S., the company is growing its capacity and working on technologies like RNAi and ADCs. Ahead of the IPO, Anthem Biosciences on Friday, 11 July 2025, raised Rs 1,016.02 crore from anchor investors. The board allotted 1.78 crore shares at Rs 570 each to 60 anchor investors. The firm reported a consolidated net profit of Rs 451.26 crore and sales of Rs 1,844.55 crore for the twelve months ended on 31 March 2025.
